UBS Reiterates Buy Rating on Surgery Partners (SGRY)

UBS analyst AJ Rice reiterated a Buy rating and $34.00 price target on Surgery Partners (NASDAQ: SGRY).

The analyst commented, "AMSURG and SGRY are the two major national surgery center chains that are not already owned by a health system or an insurer, and the potential sale of AMSURG could have implications for SGRY's valuation. On January 27th, Bain Capital offered to acquire all outstanding shares of SGRY common stock for $25.75 which translates to a ~10.5x EV/EBITDA multiple based on our current 2026 EBITDA estimates or ~12x our 2025 estimates. Some of the valuation gap between the AMSURG sale price and the Bain offer for SGRY is due to differences in calculations (trailing EBITDA for AMSURG vs. forward EBITDA for SGRY; lack of clarity on AMSURG's specific EBITDA)."

For an analyst ratings summary and ratings history on Surgery Partners click here. For more ratings news on Surgery Partners click here.

Shares of Surgery Partners closed at $23.39 yesterday.

You May Also Be Interested In

• MSG Rangers, Huron Consulting to join S&P SmallCap 600
• TrustBIX extends private placement deadline to November 21
• SpaceX in talks to access 80,000 cell sites for wireless network - Bloomberg